Jai Rautela

Money Moves

Leading the company and its push into Phase 1 trials

A Melbourne drug developer founded by two researchers and funded largely from their own pockets has signed one of the biggest preclinical drug deals to come out of Australia. Japanese drugmaker Astellas now holds the exclusive option to license Audax Biosciences' lead cancer therapy worldwide, a package worth up to $1.34 billion before royalties.

Updated 2 hours ago